kai
333b7bb8d5
Root cause: apply_patch finds anchor lines in read-cached file state, but file may have been modified between read and patch, causing stalls. Changes: - dr-verifier: disable apply_patch AND edit; force read-then-write protocol for evidence file appends - dr-analyst: document write-preferred protocol for sources.jsonl appends - dr-polisher: disable apply_patch; keep edit for small string replacements - dr-editor-in-chief / dr-translator: disable apply_patch Recovery procedure documented in dr-verifier for write failures.
185 lines
16 KiB
Markdown
185 lines
16 KiB
Markdown
# Phase 1 初扫汇总 · dual-target-rnai-pipeline-2026
|
||
|
||
- **执行日期**：2026-04-21
|
||
- **调度 agent**：dr-plan → 4 × dr-searcher（并行）
|
||
- **汇总模式**：按关键词组分节，已去重排序
|
||
- **共收集 Tier 1-2 信源**：63 条（Group A 15 + B 18 + C 15 + D 15）
|
||
|
||
---
|
||
|
||
## Group A — Dual-target siRNA Molecular Design & Pipeline Landscape
|
||
|
||
### Keywords
|
||
- **EN**：dual-target siRNA, dual-targeting siRNA, multivalent GalNAc, tandem siRNA, siRNA cocktail, di-siRNA, dendritic siRNA, branched siRNA, ARO-ANG3, ARO-APOC3, zodasiran, plozasiran, ASGPR, solbinsiran
|
||
- **ZH**：双靶点 siRNA, 多靶点 siRNA, 串联 siRNA, 多价体 siRNA, GalNAc 偶联, 瑞博 RBD4059/5044/7022, 舶望 BW-00163/40202, 圣因 PDoV-GalNAc, 必贝特 BEBT-701
|
||
|
||
### Top Sources
|
||
|
||
| ID | Title | Venue | Year | Tier | Score |
|
||
|---|---|---|---|---|---|
|
||
| src_A01 | RNAi-based drug design: considerations and future directions | Nat Rev Drug Discov | 2024 | 1 | 9.2 |
|
||
| src_A06 | A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT) | Nucleic Acids Res | 2024 | 1 | 9.3 |
|
||
| src_A11 | ARO-ANG3 Phase 1 Basket Trial — ANGPTL3 GalNAc-siRNA | Circulation | 2023 | 1 | 9.0 |
|
||
| src_A13 | Solbinsiran Phase 2 — GalNAc-siRNA targeting ANGPTL3 | The Lancet | 2024 | 1 | 9.2 |
|
||
| src_A04 | Ribofuranose-Based GalNAc-Conjugated siRNA (next-gen delivery) | Mol Ther Nucl Acids | 2025 | 1 | 9.1 |
|
||
| src_A02 | Improved GalNAc conjugation for cost-effective dual-target siRNA | Mol Ther Nucl Acids | 2024 | 1 | 9.0 |
|
||
| src_A03 | Liquid-Phase Assembly of GalNAc-siRNA (PCSK9) | Molecules | 2026 | 1 | 8.8 |
|
||
| src_A08 | US Patent 9187746B2 — Alnylam Dual-targeting siRNA | USPTO | 2015 | 1 | 8.7 |
|
||
| src_A10 | Diamine-Scaffold GalNAc-siRNA Conjugate | RSC Advances | 2024 | 1 | 8.6 |
|
||
| src_A05 | siRNA in Dyslipidemia — Systematic Review (6,651 participants) | Pharmaceuticals | 2025 | 2 | 8.5 |
|
||
| src_A07 | APOC3 + ANGPTL3 clinical landscape review | Curr Cardiol Rev | 2024 | 2 | 8.4 |
|
||
| src_A09 | Branched Multi-siRNA for GP73+hTERT (liver cancer) | Pharmaceuticals | 2025 | 2 | 8.3 |
|
||
| src_A14 | BEBT-701 dual-target AGT+PCSK9 (Chinese pipeline) | KPMG China Biotech 50 | 2025 | 2 | 8.1 |
|
||
| src_A12 | Sirnaomics GalAhead™ muRNA dual-target platform | Company PR | 2024 | 2 | 7.9 |
|
||
| src_A15 | 小核酸突围：GalNAc偶联与肝外拓展 (中国管线) | 国信证券 | 2026 | 2 | 7.8 |
|
||
|
||
### Direction Summary (EN)
|
||
|
||
Dual-target siRNA has emerged as a dominant paradigm in cardiometabolic and liver-disease therapeutics (2021-2026). Global leadership sits with Alnylam (foundational dual-targeting IP) and Arrowhead (ARO-ANG3, ARO-APOC3 in Phase 2-3); Dicerna/Novo Nordisk and Silence Therapeutics follow. Four design paradigms dominate:
|
||
1. **Covalently-linked dual siRNAs** via disulfide or nucleic acid linkers (Alnylam US9187746)
|
||
2. **Multivalent GalNAc conjugates** with triantennary or novel pyran/ribofuranose scaffolds
|
||
3. **Linear or branched di-valent siRNA** enabling programmable dual-gene silencing (Khvorova lab, Regeneron)
|
||
4. **Engineered muRNA/multi-siRNA platforms** with self-cleaving labile linkages (Sirnaomics GalAhead™)
|
||
|
||
Global pipeline ≈ 8-10 dual-target programs in Phase 1-2, predominantly APOC3+ANGPTL3, AGT+PCSK9, and complement combinations. China shows strong innovation velocity (瑞博 RBD-series, 舶望 BW-series in Phase 2, 必贝特 BEBT-701 IND-filed). Subcutaneous 6-month dosing is the norm, exploiting ASGPR's high receptor recycling (10^5-10^6/cell). Regulatory pathway de-risked: 7 of 8 approved siRNA drugs use GalNAc conjugation.
|
||
|
||
---
|
||
|
||
## Group B — Oligonucleotide Synthesis Process Landscape
|
||
|
||
### Keywords
|
||
- **EN**：phosphoramidite solid-phase, liquid-phase oligonucleotide synthesis (LPOS), enzymatic DNA/RNA synthesis, TdT, cell-free IVT, T7 polymerase, AJIPHASE, Nitto CPOS, Codexis ECO Synthesis, Ansa Biotechnologies, DNA Script, Molecular Assemblies, GreenLight Biosciences, ALE phosphoramidite
|
||
- **ZH**：寡核苷酸合成, 固相合成, 液相合成, 酶法合成, 化学酶连合成, 体外转录, 兆维科技, 小核酸 CDMO
|
||
|
||
### Top Sources
|
||
|
||
| ID | Title | Venue | Year | Tier | Score |
|
||
|---|---|---|---|---|---|
|
||
| src_B02 | Liquid-phase synthesis → chemical ligation: solution oligonucleotides | Chem Rev / Nat Catal equiv. | 2024 | 1 | 8.8 |
|
||
| src_B06 | Enzymatic de novo oligonucleotide synthesis (review) | Biotechnol Adv | 2025 | 1 | 8.7 |
|
||
| src_B03 | Reaction pathways of in vitro DNA synthesis | Cell Rep Phys Sci | 2025 | 1 | 8.6 |
|
||
| src_B01 | LPOS Past, Present, Future (foundational review) | OPR&D | 2019 | 1 | 8.5 |
|
||
| src_B09 | Multi-enzymatic bulk DNA synthesis | Nature npj Vaccines | 2025 | 1 | 8.4 |
|
||
| src_B05 | ALE phosphoramidite platform — long RNA (100-215 nt) | PMC | 2024 | 1 | 8.3 |
|
||
| src_B18 | NMPA CDE 化学合成寡核苷酸技术指导原则 (regulatory) | NMPA | 2026 | 1 | 8.2 |
|
||
| src_B10 | TdT variant engineering overcoming dATP bottleneck | Cell Rep Methods | 2025 | 1 | 8.1 |
|
||
| src_B14 | Ajinomoto AJIPHASE® for PMO / applicable to siRNA | Company | 2025 | 2 | 7.9 |
|
||
| src_B08 | EDS: 1.5-7 kb complex sequences (DNA Script review) | Drug Disc World | 2025 | 2 | 7.9 |
|
||
| src_B13 | GreenLight cell-free RNA — <$1/g at 2k L | Axial + corp | 2023-25 | 2 | 7.8 |
|
||
| src_B04 | Liquid-phase GalNAc-siRNA assembly validation | PMC | 2024 | 2 | 7.8 |
|
||
| src_B11 | Codexis ECO Synthesis: 3 kg clinical siRNA batch (2025) | Codexis | 2025 | 2 | 7.6 |
|
||
| src_B12 | Codexis-Bachem enzymatic ligation demonstration | Bachem/Codexis | 2025 | 2 | 7.7 |
|
||
| src_B16 | 兆维 Hongene chemoenzymatic ligation platform (>95% purity) | 医药魔方 | 2025 | 2 | 7.6 |
|
||
| src_B15 | Codexis-Nitto Denko Avecia enzymatic collaboration | Manuf Chemist | 2025 | 2 | 7.5 |
|
||
| src_B07 | Enzymatic DNA Synthesis Market 2025-2030 | Mordor Intel | 2025 | 2 | 7.5 |
|
||
| src_B17 | Peptide & Oligo CDMO Market (GMP 60.8%, fill-finish 14% CAGR) | Mordor Intel | 2025 | 2 | 7.4 |
|
||
|
||
### Direction Summary (EN)
|
||
|
||
Oligonucleotide manufacturing for dual-target siRNA is transitioning from monoculture to pluralism. Classical **solid-phase phosphoramidite** remains dominant (>60% CDMO volume, >99% per-cycle coupling, established GMP) but capital-intensive ($2-5M per column-scale synthesizer). Three emerging modalities are gaining share:
|
||
- **Liquid-phase synthesis (LPOS)** — Ajinomoto AJIPHASE, Nitto CPOS — cuts solvent waste 50-70%, simplifies scale-up, but long-sequence complexity remains challenging.
|
||
- **Enzymatic template-free synthesis** — Ansa, DNA Script, Molecular Assemblies — accesses 600-750 bp single oligos and complex secondary structures; engineered TdT variants are breaking the dATP bottleneck.
|
||
- **Enzymatic ligation (chemoenzymatic)** — Codexis ECO Synthesis, Codexis/Bachem — decouples synthesis scale from length by joining short high-purity fragments; 3 kg clinical siRNA batch demonstrated in 2025.
|
||
- **Cell-free IVT** — GreenLight Biosciences — <$1/g dsRNA at 2 k L; deployed in agriculture and mRNA, applicable to long therapeutic RNA.
|
||
|
||
**Economics**: solid-phase wins on short campaigns; LPOS/ligation on complexity & scale-up; enzymatic/cell-free on sustainability and long-construct access. Chinese NMPA 2026 draft guidance formally recognizes chemoenzymatic ligation as a peer modality. Enzymatic DNA synthesis market projected $500M-$8.77B by 2030 (20-30% CAGR).
|
||
|
||
---
|
||
|
||
## Group C — GalNAc Conjugation Chemistry & Immobilized Enzyme Catalysis
|
||
|
||
### Keywords
|
||
- **EN**：GalNAc conjugation, triantennary GalNAc ligand, CuAAC/SPAAC click chemistry, oligonucleotide bioconjugation, immobilized enzyme catalysis, glycosyltransferase, CLEA, lipase desymmetrization, linker chemistry, hydroxyprolinol, RNase T1 QC, nuclease P1
|
||
- **ZH**：GalNAc 偶联, 三触角 GalNAc, 多价配体, 支架化学, 点击化学, 固定化酶, 糖基转移酶, 双靶点 RNAi 偶联
|
||
|
||
### Top Sources
|
||
|
||
| ID | Title | Venue | Year | Tier | Score |
|
||
|---|---|---|---|---|---|
|
||
| src_C05 | Immobilized Enzyme Cascade for Targeted Glycosylation (SUGAR-TARGET) | Nat Chem Biol | 2023 | 1 | 9.3 |
|
||
| src_C01 | Liquid-phase assembly of GalNAc-siRNA conjugates | PubMed | 2024 | 1 | 9.2 |
|
||
| src_C04 | GalNAc-ASGPR advancement review | Biomed Pharmacother | 2025 | 1 | 8.9 |
|
||
| src_C12 | A Hitchhiker's Guide to Click Chemistry with Nucleic Acids | Chem Rev | 2020 | 1 | 8.8 |
|
||
| src_C03 | Expansion of Conjugate Space of RNAi — 3' ligand optimization | J Med Chem | 2024 | 1 | 8.8 |
|
||
| src_C07 | Practical Synthesis of Triantennary GalNAc (multi-gram) | OPR&D | 2024 | 1 | 8.7 |
|
||
| src_C09 | Enzyme Immobilization + Bio-Orthogonal Chemistry (comprehensive) | Green Chem (RSC) | 2024 | 1 | 8.6 |
|
||
| src_C02 | Ribofuranose-based GalNAc: kilogram-scale CPG synthesis | Nat Biotechnol | 2024 | 1 | 9.0 |
|
||
| src_C14 | Targeted RNA Degradation / QC enzymes (RNase T1, P1) | Chem Rev | 2024 | 1 | 8.5 |
|
||
| src_C06 | Model-Assisted Trivalent GalNAc Click Synthesis | ACS Omega | 2024 | 2 | 8.5 |
|
||
| src_C08 | Enzyme Immobilization in Biocatalysis (tutorial) | Chem Rev | 2023 | 1 | 8.4 |
|
||
| src_C11 | Automated Solid-Phase Click Oligonucleotide Conjugation | Bioconjug Chem | 2017 | 1 | 8.3 |
|
||
| src_C13 | Microgels with Immobilized Glycosyltransferases | Biomacromolecules | 2024 | 2 | 8.1 |
|
||
| src_C10 | Lipase CLEA in Deep Eutectic Solvents | J Biotechnol | 2020 | 2 | 7.9 |
|
||
| src_C15 | Sustainability Challenges in Oligonucleotide Manufacturing | J Org Chem | 2021 | 2 | 7.8 |
|
||
|
||
### Direction Summary (EN)
|
||
|
||
Approved and late-stage RNAi drugs depend overwhelmingly on **triantennary GalNAc conjugates** for ASGPR-mediated hepatocyte targeting (Alnylam's inclisiran, givosiran, lumasiran, vutrisiran). Conjugation is achieved via **solid-phase (on-column) or post-synthetic liquid-phase assembly** using CuAAC click or amide bond formation, with engineered linkers (amide, hydroxyprolinol, phosphodiester-adjacent) balancing serum stability and lysosomal release. Kilogram-scale GalNAc building-block synthesis is now routine via convergent routes and solid-supported phosphoramidites.
|
||
|
||
**Immobilized enzyme catalysis** is the critical emerging frontier:
|
||
- Glycosyltransferases (GalT, GnTI, SiaT) immobilized via biotin-streptavidin or CLEA cross-linking → scalable polysaccharide intermediate synthesis with reusability and reduced substrate promiscuity.
|
||
- Lipase-catalyzed desymmetrization of GalNAc precursors → fewer synthetic steps, better atom economy.
|
||
- Immobilized nucleases (RNase T1, P1) and phosphatases → critical QC for duplex assembly verification.
|
||
|
||
**Dual-target architectures** impose new constraints: extended payloads (50-70 nt) demand higher GalNAc cluster valency; branched dendritic scaffolds and triazole linkers add synthetic complexity. **Industrial-scale CuAAC remains bottlenecked by copper toxicity and solvent requirements** — SPAAC and enzyme-catalyzed ligation are the most promising next-generation alternatives.
|
||
|
||
---
|
||
|
||
## Group D — Upstream Supply Chain & Domestic Substitution Opportunities
|
||
|
||
### Keywords
|
||
- **EN**：oligonucleotide CDMO capacity, phosphoramidite monomers (Hongene/ChemGenes/Ajinomoto), CPG solid support (Prime Synthesis/Kinovate/Nitto), industrial enzymes (NEB/Takara/Codexis/Vazyme), GalNAc ligand suppliers, BIOSECURE Act, IRA reshoring
|
||
- **ZH**：兆维 Hongene, 金斯瑞 GenScript, 诺唯赞 Vazyme, 凯莱英 KaiLai, 药明康德 WuXi, 博腾, 九洲, 锐博生物, 小核酸 CDMO, 国产替代, 固相载体, 工业用酶, 亚磷酰胺
|
||
|
||
### Top Sources
|
||
|
||
| ID | Title | Venue | Year | Tier | Score |
|
||
|---|---|---|---|---|---|
|
||
| src_D02 | Synthesis of GalNAc-Oligonucleotide Conjugates (PNAS primary protocol) | PNAS | 2021 | 1 | 8.4 |
|
||
| src_D13 | Advanced siRNA Design & 2'-F/2'-OMe monomer optimization | Nat Biotechnol | 2019 | 1 | 8.2 |
|
||
| src_D03 | Bioconjugated Oligonucleotides: phosphoramidite chemistry + suppliers | Sem Cell Dev Biol | 2019 | 1 | 8.1 |
|
||
| src_D14 | BIOSECURE Act becomes law (2025 NDAA §851) | Arnold & Porter | 2025 | 1 | 7.8 |
|
||
| src_D06 | Codexis ECO Synthesis RNA Manufacturing (>75% yield) | Codexis | 2024-25 | 2 | 7.5 |
|
||
| src_D09 | 兆维 Hongene Shanghai Fengxian commercial base (1 kg/batch, 48 lines) | 医药魔方 | 2025 | 2 | 7.4 |
|
||
| src_D11 | KPMG China Biotech 50 — 兆维/凯莱英/药明 oligo roadmap | KPMG | 2025 | 2 | 7.3 |
|
||
| src_D04 | Prime Synthesis CPG gold standard (LGC Biosearch) | LGC | 2024 | 2 | 7.3 |
|
||
| src_D01 | Evaluate Pharma CDMO Intelligence Report (7.29% CAGR 2023-28) | Evaluate | 2023-26 | 2 | 7.2 |
|
||
| src_D10 | GenScript 2025 results ($959.5M, +61.4% YoY) | HK.1548 filing | 2026 | 2 | 7.2 |
|
||
| src_D05 | NittoPhase HL high-load solid support (40% cost cut) | Kinovate/Nitto | 2025 | 2 | 7.1 |
|
||
| src_D15 | Phosphoramidite Market (NA 40% share, APAC 7.43% CAGR) | Mordor Intel | 2024 | 2 | 7.0 |
|
||
| src_D08 | Codexis T7 RNA polymerase / ligation services | Codexis | 2025 | 2 | 6.9 |
|
||
| src_D12 | Smartanalyst China Oligo CDMO 2025-2030 | 腾讯/医药魔方 | 2025 | 2 | 6.9 |
|
||
| src_D07 | Takara RNase H / DNase I / T7 RNAP GMP-grade (Kusatsu) | Takara | 2024 | 2 | 6.8 |
|
||
|
||
### Direction Summary (EN)
|
||
|
||
The dual-target siRNA upstream supply chain shows **three high-value choke points** with largest domestic-substitution windows:
|
||
|
||
**1. Phosphoramidite monomers** — 2'-OMe, 2'-F, GalNAc-phosphoramidite supply concentrated in Ajinomoto Bio-Pharma, ChemGenes, Hongene (兆维). Hongene already achieves 98% purity oligo API at 1 kg/batch with 48-line capacity and NMPA+FDA+EMA QA. Domestic R&D under "十四五" biotech localization targets projects 30-50% import-reliance reduction by 2027.
|
||
|
||
**2. Solid supports (CPG & polymeric)** — Gold-standard CPG dominated by LGC Biosearch (Prime Synthesis); Nitto Denko's NittoPhase HL offers 40% raw-material cost advantage at 350-400 µmol/g loading. Chinese CDMOs have capital access to catch up quickly; geographic diversification (US + EU + JP) is built in at Tier 2 suppliers.
|
||
|
||
**3. Industrial enzymes & cell-free systems** — T7 RNA polymerase, RNase H, RNA ligase bottlenecks are being attacked by Codexis (engineered variants), Takara GMP nuclease (Kusatsu), NEB PURExpress. **BIOSECURE Act (Dec 2025)** restricts WuXi, BGI, Complete Genomics from U.S. federal contracts — forcing diversification to Japan, Europe, India; a **18-36 month capacity-deficit window** opens a $200-400M domestic-substitution opportunity in NA/EU through 2028.
|
||
|
||
---
|
||
|
||
## 交叉发现（Cross-Group Insights）
|
||
|
||
1. **Alnylam + Arrowhead 主导设计范式 vs. 中国主导规模化工艺**：海外赢在分子设计 IP（US9187746 等），国内兆维 Hongene 赢在 GMP 规模化和工艺复刻速度；Sirnaomics、瑞博、舶望、必贝特构成国内设计端第二梯队。
|
||
2. **Codexis 酶法路线贯穿 B/C/D 组**：其 ECO Synthesis 平台同时被 Bachem、Nitto Denko Avecia、RNA CDMO 采纳，是酶催化替代传统固相最关键的"上游供应商×工艺平台"双重节点。
|
||
3. **NMPA 2026 draft 指导原则（src_B18）**是关键监管变量：首次将化学酶连合成法列入正式 CMC 指导范围，与 BIOSECURE Act 形成"中国给工艺放行、美国给供应商关门"的对冲格局。
|
||
4. **多价 GalNAc + 酶法偶联** 是下一代双靶点 siRNA 的工艺交汇点：A 组的 Sirnaomics muRNA、瑞博 RiboGalSTAR™、舶望 RADS 平台，都需要 C 组描述的高价态 GalNAc 簇 + 固定化糖基转移酶配套，D 组需要对应的三触角 GalNAc 单体与 CuAAC/SPAAC 催化剂供应。
|
||
|
||
---
|
||
|
||
## 识别的关键数据缺口（Phase 2 需补）
|
||
|
||
- 各家双靶点管线的 **具体合成工艺细节**（固相 vs. 液相 vs. 酶连）在公开文献中披露度不均 → Phase 2 需从专利说明书补
|
||
- 国内企业 **亚磷酰胺单体国产化率** 的定量数据仅见于券商研报（Tier 2），需交叉 NMPA/进出口数据
|
||
- **固定化酶用于 siRNA 偶联** 的工业案例偏少（学术层面多） → Phase 2 需深挖 Codexis 专利、GreenLight 工艺包
|
||
- **双靶点 siRNA 的分离纯化工艺**（IEX、HIC、离子对 RP-HPLC 对支架分子的选择性）基本空白 → Phase 2 独立深研
|
||
|
||
---
|
||
|
||
**下一步**：dr-plan 据此生成 `framework.md`（8-10 章双语大纲），等用户确认后进 Phase 2。
|